| Title |
Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications
|
|---|---|
| Published in |
Current Psychiatry Reports, May 2015
|
| DOI | 10.1007/s11920-015-0594-9 |
| Pubmed ID | |
| Authors |
Chiara Fabbri, Alessandro Serretti |
| Abstract |
The pharmacogenetics of antidepressants has been not only a challenging but also frustrating research field since its birth in the 1990s. Indeed, great expectations followed the first evidence of familiar aggregation of antidepressant response. Despite the progress from candidate gene studies to genome-wide association studies (GWAS), results fell out the expectations and they were often inconsistent. Anyway, the cumulative evidence supports the involvement of some genes and molecular pathways in antidepressant efficacy. The best single genes are SLC6A4, HTR2A, BDNF, GNB3, FKBP5, ABCB1, and cytochrome P450 genes (CYP2D6 and CYP2C19). Molecular pathways involved in inflammation and neuroplasticity show the greatest support. The first studies evaluating benefits of genotype-guided antidepressant treatments provided encouraging results and confirmed the relevance of SLC6A4, HTR2A, ABCB1, and cytochrome P450 genes. Further progress in genotyping and data analysis would allow to move forward and complete the understanding of antidepressant pharmacogenetics and its translation into clinical applications. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| New Zealand | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 94 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 18% |
| Student > Bachelor | 16 | 17% |
| Student > Master | 11 | 11% |
| Student > Doctoral Student | 8 | 8% |
| Researcher | 8 | 8% |
| Other | 14 | 15% |
| Unknown | 22 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 24% |
| Biochemistry, Genetics and Molecular Biology | 12 | 13% |
| Agricultural and Biological Sciences | 10 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 9% |
| Neuroscience | 7 | 7% |
| Other | 13 | 14% |
| Unknown | 22 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2017.
All research outputs
#14,810,408
of 22,803,211 outputs
Outputs from Current Psychiatry Reports
#894
of 1,190 outputs
Outputs of similar age
#147,686
of 265,295 outputs
Outputs of similar age from Current Psychiatry Reports
#18
of 28 outputs
Altmetric has tracked 22,803,211 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,190 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.8. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,295 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.